REPLIMUNE GROUP, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REPLIMUNE GROUP, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $10.36M, a 90.36% decline year-over-year.
- REPLIMUNE GROUP, INC. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $107.53M.
- REPLIMUNE GROUP, INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $48.20M.
- REPLIMUNE GROUP, INC. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $149.85M.
- REPLIMUNE GROUP, INC. stock issued during period, value, new issues for fiscal 2026 was $31.15M, a 80.00% decline from fiscal 2025.
- REPLIMUNE GROUP, INC. stock issued during period, value, new issues for fiscal 2025 was $155.73M.
- REPLIMUNE GROUP, INC. stock issued during period, value, new issues for fiscal 2023 was $149.85M.
- REPLIMUNE GROUP, INC. stock issued during period, value, new issues for fiscal 2021 was $286.11M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $31.15M 10-K · filed 2026-06-29 | |
| 2025-12-31 | $10.36M 10-Q · filed 2026-02-03 | |
| 2025-03-31 | $155.73M 10-K · filed 2026-06-29 | |
| 2024-12-31 | $107.53M 10-Q · filed 2026-02-03 | |
| 2024-06-30 | $48.20M 10-Q · filed 2026-02-03 | |
| 2023-03-31 | $149.85M 10-K · filed 2024-05-16 | |
| 2022-12-31 | $149.85M 10-Q · filed 2024-02-08 | |
| 2022-09-30 | $6.40M 10-Q · filed 2024-02-08 | |
| 2022-06-30 | $31.04M 10-Q · filed 2024-02-08 | |
| 2021-03-31 | $286.11M 10-K · filed 2022-05-19 | |
| 2020-12-31 | $211.22M 10-Q · filed 2022-02-03 | |
| 2020-06-30 | $74.88M 10-Q · filed 2022-02-03 | |
| 2019-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-28 | $101.18M 10-K · filed 2019-06-28 |
| 2018-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14 | |
| 2018-09-30 | $101.18M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |